skip to main content

Welcome to Evgen Pharma PLC

Evgen Pharma is a clinical stage drug development company developing sulforaphane-based medicines focussed on the treatment of cancer and inflammation. Our pipeline and lead compound SFX-01 is derived from our proprietary Sulforadex® technology. We are also researching a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to turn this scientific promise into commercially successful products, addressing important clinical needs.

Evgen Pharma Image Strategy

About

Evgen Pharma has a clear strategy for driving shareholder value from its technology

Read more

Evgen Pharma Image History

Management

Evgen Pharma has attracted a highly experienced commercial, scientific and advisory team

Read more

Evgen Pharma Image Organisation

History

Founded in 2007, Evgen Pharma has evolved quickly into a clinical stage company

Read more

Investors

Evgen Pharma is a publicly quoted company. Its shares trade under the ticker symbol EVG.

Find out more

Pipeline

Evgen Pharma is a clinical stage drug development company developing sulforaphane-based medicines focussed on the treatment of cancer and inflammation. Our pipeline and lead compound SFX-01, a synthetic, stabilised form of sulforaphane, is made using our proprietary Sulforadex® technology. We are also researching a number of analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to turn this scientific promise into commercially successful products, addressing important clinical needs.

METASTATIC BREAST CANCER

Breast cancer is the biggest cause of cancer deaths in women worldwide. In around 75% of breast cancers, the hormone oestrogen plays a key part in tumour growth

Read more

GLIOMA AND GLIOBLASTOMA

Glioma is the most common form of brain tumour affecting around 5 per 100,000 people. The more severe, grade IV classification, glioblastoma, is a very serious form of brain tumour

Read more

SFX-01: ACUTE RESPIRATORY DISTRESS SYNDROME (‘ARDS’)

STAR trial led by Professor James Chalmers at the University of Dundee will investigate whether SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome (ARDS)

Read more

Technology

The Sulforadex® stabilisation technology means that sulforaphane, and related analogues, can be delivered as a stable active in an oral pharmaceutical product.

Find out more